The Food and Drugs Administration has issued a safety warning following six cases of haemorrhagic or necrotising pancreatitis were linked to concurrent use of exenatide (Byetta®). Two of these cases proved to be fatal.
Healthcare professionals are advised that there are no clinical signs or symptoms that distinguish acute haemorrhagic or necrotising pancreatitis from less severe form of pancreatitis. It is therefore recommended that exenatide and other potentially suspect drugs should be immediately discontinued in cases of suspected pancreatitis.
Pancreatitis is already discussed in the Summary of Product Characteristics but it is likely that stronger and more prominent warnings will be added.
Action: Clinicians should be aware of this safety concern and react to stop medication rapidly if pancreatitis is suspected.
|« SMC August Update||Co-proxamol withdrawal reduces suicides »|